Latest Insider Transactions at Akero Therapeutics, Inc. (AKRO)
This section provides a real-time view of insider transactions for Akero Therapeutics, Inc. (AKRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akero Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akero Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.94%
|
$1,125,000
$45.11 P/Share
|
|
Jun 01
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.78%
|
$75,000
$3.49 P/Share
|
|
May 19
2023
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
120,000
+18.75%
|
$5,040,000
$42.0 P/Share
|
|
May 01
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.9%
|
$1,125,000
$45.25 P/Share
|
|
May 01
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.44%
|
$0
$0.62 P/Share
|
|
Apr 18
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+8.9%
|
$0
$0.62 P/Share
|
|
Apr 03
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-3.18%
|
$950,000
$38.36 P/Share
|
|
Apr 03
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.96%
|
$0
$0.62 P/Share
|
|
Mar 10
2023
|
William Richard White Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
641
-2.71%
|
$27,563
$43.47 P/Share
|
|
Mar 10
2023
|
Jonathan Young Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-0.34%
|
$27,262
$43.47 P/Share
|
|
Mar 10
2023
|
Catriona Yale Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
701
-0.86%
|
$30,143
$43.46 P/Share
|
|
Mar 10
2023
|
Andrew Cheng President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,706
-0.46%
|
$73,358
$43.47 P/Share
|
|
Mar 10
2023
|
Timothy Rolph Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
603
-0.32%
|
$25,929
$43.47 P/Share
|
|
Mar 01
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.14%
|
$1,150,000
$46.44 P/Share
|
|
Mar 01
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.94%
|
$0
$0.62 P/Share
|
|
Feb 01
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.14%
|
$1,225,000
$49.46 P/Share
|
|
Feb 01
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.94%
|
$0
$0.62 P/Share
|
|
Jan 13
2023
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.48%
|
$250,000
$50.55 P/Share
|
|
Jan 03
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.08%
|
$1,300,000
$52.54 P/Share
|
|
Jan 03
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.94%
|
$0
$0.62 P/Share
|
|
Jan 03
2023
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,777
-4.53%
|
$473,958
$54.64 P/Share
|
|
Jan 03
2023
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,777
+4.34%
|
$0
$0.62 P/Share
|
|
Dec 29
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,316
-4.93%
|
$1,015,800
$50.97 P/Share
|
|
Dec 29
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,816
+3.57%
|
$218,848
$28.35 P/Share
|
|
Dec 28
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,700
-0.83%
|
$85,000
$50.0 P/Share
|
|
Dec 28
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+0.82%
|
$47,600
$28.35 P/Share
|
|
Dec 28
2022
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
999
-4.06%
|
$48,951
$49.76 P/Share
|
|
Dec 28
2022
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
999
+3.9%
|
$6,993
$7.01 P/Share
|
|
Dec 27
2022
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,001
-44.58%
|
$931,049
$49.77 P/Share
|
|
Dec 27
2022
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,001
+30.83%
|
$133,007
$7.01 P/Share
|
|
Dec 27
2022
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-6.41%
|
$612,500
$49.57 P/Share
|
|
Dec 27
2022
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+3.05%
|
$37,500
$3.49 P/Share
|
|
Dec 16
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+2.24%
|
$0
$0.62 P/Share
|
|
Dec 12
2022
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.75%
|
$215,000
$43.48 P/Share
|
|
Dec 09
2022
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+9.52%
|
-
|
|
Dec 09
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+8.64%
|
-
|
|
Dec 09
2022
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
52,351
+12.62%
|
-
|
|
Dec 09
2022
|
Catriona Yale Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+17.38%
|
-
|
|
Dec 09
2022
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,195
+44.83%
|
-
|
|
Dec 01
2022
|
Skorpios Trust |
SELL
Open market or private sale
|
Indirect |
1,636,000
-33.33%
|
$70,348,000
$43.5 P/Share
|
|
Dec 01
2022
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.12%
|
$460,000
$46.07 P/Share
|
|
Dec 01
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.03%
|
$0
$0.62 P/Share
|
|
Nov 30
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Indirect |
12,030
-3.83%
|
$565,410
$47.02 P/Share
|
|
Nov 30
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Direct |
11,101
-3.84%
|
$521,747
$47.02 P/Share
|
|
Nov 16
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,947
-1.05%
|
$177,615
$45.75 P/Share
|
|
Nov 15
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,138
-1.64%
|
$141,210
$45.04 P/Share
|
|
Nov 10
2022
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.25%
|
$195,000
$39.68 P/Share
|
|
Nov 01
2022
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.04%
|
$430,000
$43.21 P/Share
|
|
Nov 01
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.03%
|
$0
$0.62 P/Share
|
|
Oct 28
2022
|
Seth Loring Harrison |
SELL
Open market or private sale
|
Indirect |
22,965
-6.31%
|
$918,600
$40.7 P/Share
|